Download PDFPDF

1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address